Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine with Rapamycin or Ribavirin in High Risk AML
NCT02109744Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Mar 2014
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus, ribavirin in acute myeloid leukemia (AML), sponsored by University of Rochester. Started Mar 2014; status: completed.
02
Drugs
sirolimusribavirin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02109744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109744.